Ra Capital Management, L.p. bought $20M of SION
director, owner at Sionna Therapeutics, Inc.. 1,125,000 shares at an average of $18.00, traded Feb 10, 2025, filed Feb 10, 2025.
Score components
- +15RoleDirector
- +25Trade size$20.2M at market
- +3Relative to holdingsHoldings up 19%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-003504, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 10, 2025 | CConversion Common Stockindirect: See footnotes | +5,021,990 | - | - | 5,900,779 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Common Stockindirect: See footnotes | +527,444 | - | - | 869,651 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Common Stockindirect: See footnotes | +2,222,084 | - | - | 2,222,084 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Common Stockindirect: See footnotes | +179,975 | - | - | 327,808 | Feb 10, 2025 |
| Feb 10, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +1,022,586 | $18.00 | $18M | 6,923,365 | Feb 10, 2025 |
| Feb 10, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +102,414 | $18.00 | $1.8M | 2,324,498 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series Seed Preferred Stockderivativeindirect: See footnotes | -819,153 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series Seed Preferred Stockderivativeindirect: See footnotes | -319,069 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series Seed Preferred Stockderivativeindirect: See footnotes | -138,054 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,229,830 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -451,580 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -124,908 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -923,773 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -2,155,469 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -4,364,874 | $0.00 | $0 | 0 | Feb 10, 2025 |
| Feb 10, 2025 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -1,091,219 | $0.00 | $0 | 0 | Feb 10, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 53Moderate | Sionna Therapeutics, Inc. | Tpg Gp A, LLC owner | $20M 1,125,000 shares | +20% | |
| 50Moderate | Sionna Therapeutics, Inc. | Atlas Venture Fund XI, L.P. owner | $1.1M 60,000 shares | +8% | |
| 58Moderate | Sionna Therapeutics, Inc. | Bruce Booth director | $1.1M 60,000 shares | +8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.